<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The administration of cytotoxic chemotherapy may be complicated by the emergence of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, frequently determining hospital admission and intravenous treatment with broad spectrum antibiotics </plain></SENT>
<SENT sid="1" pm="."><plain>Frequently, it is necessary to reduce the dose or to delay the administration of the cytotoxic drugs reducing the relative dose intensity of the chemotherapy regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Granulocyte growth factors stimulate the proliferation and differentiation of neutrophils and reduce the number of days of severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> associated with cytotoxic chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>They are also indicated for the collection of hematopoietic progenitors for autologous and allogeneic transplantation, as well as in non malignant diseases associated with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This article reviews the evidence supporting the use of granulocyte growth factors in Hematology </plain></SENT>
</text></document>